Expand SBIO Menu
SBIO MENU

SBIO ETF Profile


Family: ALPS
Name: ALPS Medical Breakthroughs ETF
Inception Date: 31-Dec-2014
Termination Date:
Investment Objective: The Fund seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (ticker symbol PMBI) (the "Underlying Index"). The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States and in the stocks of companies operating in the biotechnology sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the S-Network Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
Prospectus
Top 10 Holdings
APOGEE THERAPEUTICS INC APGE 4.4500%
CG ONCOLOGY INC CGON 3.4500%
XENON PHARMACEUTICALS INC XENE 3.1300%
TRAVERE THERAPEUTICS INC TVTX 2.9700%
ORUKA THERAPEUTICS INC ORKA 2.9700%
VERADERMICS INC MANE 2.8800%
DIANTHUS THERAPEUTICS INC DNTH 2.8300%
DEFINIUM THERAPEUTICS INC DFTX 2.6700%
EDGEWISE THERAPEUTICS INC EWTX 2.4200%
ACADIA PHARMACEUTICALS INC ACAD 2.3500%
Top 10 Holdings Weight: 30.1%
Number of Holdings: 107
Shares Outstanding: 2,925,000
Total Net Assets: 185,006,300
NAV: 63.12
Net Expense Ratio: 0.50%
Asset Class: Equities (Stocks)
Developed or Emerging: Developed Market Funds
Country: US
Region:
Strategy:
Currency:
Commodity:
Sector: Healthcare
Industry: Biotech
Dividend Type:
Tax Exempt State:
Maturity Duration:
Market Cap: SMID (Small & Mid) Cap
Credit Quality:
Mortgage Bond Types:
Bond Type:
Gov't Bond Types:
Reit Type:
Leverage Direction/Factor:
Is Currency Hedged: No
US or Ex-US: Domestic
Market Data Delayed 15 Minutes